Search results
Democrats ramp up patent fight with drug industry in bid to lower prices
Washington Post· 6 days agoDemocrats have hit on a new tactic in their long battle with drug companies: challenge patents that...
USPTO Unveils Examiner Guidance on Searching Drug-related Applications | JD Supra
JD Supra· 2 days agoTo recap, in one of its first acts, the Administration promulgated Executive Order 14036 (July 9, 2021), which contained the assertion that "Americans are paying too much for prescription ...
FTC Warns Pharma Companies It Means Business with Its Orange Book Listing Policy | JD Supra
JD Supra· 1 day agoActavis). It will be recalled that the FTC spent the better part of a decade attacking the practice of innovator drug companies settling ANDA litigation by providing payments ...
Independent pharmacies at disadvantage with franchise companies
Tahlequah Daily Press, Okla. via Yahoo News· 2 days agoJun. 10—High drug costs in the U.S. often prompt patients to order from other countries, and smaller rural and independent pharmacies suffer from requirements for sourcing ...
The U.S. is fighting high drug prices. Big Pharma isn't sweating — yet
Quartz· 3 days agoA key goal of the Biden administration has been to rein in healthcare costs. As the administration...
State Drug Pricing Boards Forge Ahead With Eyes on Amgen Suit
Bloomberg Law· 3 days agoState affordability boards seeking to limit what health plans pay for prescription drugs are confident they will withstand legal challenges as Colorado battles what’s expected ...
JD Supra: Better Health Care Newsletter
JD Supra· 7 days agoFederal officials have capped the cost of insulin at $35 a month. For now, that gives relief only to patients 65 and older covered by Medicare. Big Pharma in recent years has flouted that charitable intent.
Nayzilam and cost: Reducing long-term drug costs and more
Medical News Today· 6 days agoNayzilam (midazolam) is a brand-name nasal spray that’s prescribed for a type of seizure that occurs...
Novo Nordisk's Ozempic sales double to $700 M in China, driven by weight-loss demand | Invezz
Invezz· 7 days agoLast year, Novo Nordisk, the Danish pharmaceutical giant, witnessed a significant surge in the sales...
Citi maintains buy on Axsome, price target steady at $125 By Investing.com
Investing.com· 15 hours agoOn Wednesday, Citi reaffirmed its Buy rating on Axsome Therapeutics (NASDAQ:AXSM) with a consistent...